Navigation Links
iBio, Inc. Receives Anticipated Notice from NYSE MKT that Company is Below Certain Continued Listing Standards
Date:3/4/2013

NEWARK, Del., March 4, 2013 /PRNewswire/ -- iBio, Inc. (NYSE MKT: IBIO) today announced that it has been notified by the NYSE MKT (the "Exchange") Staff that the Company is currently not in compliance with the listing standard set forth in Section 1003(a)(ii) of the NYSE MKT Company Guide.  This standard applies if a listed company has stockholders' equity of less than $4,000,000 and net losses in three of its most recent four years. 

(Logo:  http://photos.prnewswire.com/prnh/20120419/NY91086LOGO)

As previously announced, in December 2012 the Company submitted, and the Exchange subsequently accepted a plan of compliance which is intended to restore the Company's compliance with the Exchange's continued listing criteria set forth in Section 1003(a)(iii) of the NYSE MKT Company Guide.  These listing criteria apply if a listed company has stockholders' equity of less than $6,000,000 and net losses in its five most recent years.  

Due to the higher stockholder's equity requirement contained in Section 1003(a)(iii), the Company is not required to submit an additional plan of compliance in connection with the deficiency noticed in the Exchange's most recent correspondence.  

The Company, pursuant to an extension of time previously granted by the Exchange, must regain compliance with Exchange's continued listing standards, including the criteria contained in each of Section 1003(a)(ii) and Section 1003(a)(iii), by October 14, 2013.  During this extension period, the Company will be subject to periodic review by the Staff of the Exchange.  The failure by the Company to make progress consistent with the accepted plan or to regain compliance with the continued listing standards by the end of the extension period could result in the Company being delisted from the Exchange.

About iBio, Inc.
iBio develops and offers product applications of its iBioLaunch™ and iBioModulator™ platforms, providing collaborators full support for turn-key implementation of its technology for both proprietary and biosimilar products. The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. Advantages over other systems may include: success with proteins difficult or impossible to produce with other methods; broadly applicable to biologics, including therapeutic proteins and vaccines; production time measured in weeks instead of months or more. Additional benefits may include: surge capacity for remedial action against bioterrorism and pandemic disease; product entry that is unconstrained by traditional process patents, and significantly lower capital and operating costs for comparable production. The iBioModulator platform is complementary to the iBioLaunch platform and is designed to significantly improve vaccine products by increasing potency and lengthening duration of effect. The iBioModulator platform can be used with any recombinant expression technology for vaccine development and production. Further information is available at: www.ibioinc.com.

Forward-Looking Statements 

Various statements in this release concerning iBio's future expectations, plans and prospects, including without limitation, iBio's ability to regain compliance with the continued listing standards on a timely basis constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995.  Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including, without limitation, iBio's failure to make progress consistent with the plan approved by the Exchange or iBio's failure to meet other criteria necessary for continued listed on the Exchange, as well as those risks more fully discussed in the "Risk Factors" section of the documents filed by the Company with the Securities and Exchange Commission.  In addition, any forward-looking statements represent iBio's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.  iBio does not assume any obligation to update any forward-looking statements.

Contacts

iBio, Inc.
Andrea Corcoran
302-355-0624
acorcoran@ibioinc.com

 


'/>"/>
SOURCE iBio, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. iBio, Inc. Receives Notice from NYSE MKT Staff that Company Currently is Below Certain Continued Listing Standards
2. iBio, Inc. and GE Healthcare form new global alliance
3. iBio, Inc. Prices $10 Million Public Offering
4. iBio, Inc. Submits Plan to Satisfy NYSE Amex Continued Listing Standards
5. Zyomyx, Inc. Receives ISO 13485: 2003 Certification
6. New Science Fiction Novel Paints Terrifying Picture of Dystopian Future: Young Author Receives Glowing Reviews
7. Rosemary Gladstar Receives First-Annual ABC Mark Blumenthal Herbal Community Builder Award
8. Next Breath Receives ISO/IEC 17025:2005 Accreditation from the American Association for Laboratory Accreditation
9. OsteoFabâ„¢ Patient Specific Cranial Device Receives 510(k) Approval
10. Discovery Labs Receives $30 Million Funding Commitment from Deerfield Management
11. Venaxis Executes First Commercial Development Agreement and Receives Purchase Order from EMELCA Bioscience for Initial EU Launch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... , Feb. 4, 2016 ContraVir Pharmaceuticals, Inc. ... the development and commercialization of targeted antiviral therapies, announced ... Investor Conference 2016, to be held February 8-9, 2016, ... Group,s 2016 Disruptive Growth & Healthcare Conference, taking place ... 10-11, 2016. James Sapirstein , Chief Executive ...
(Date:2/4/2016)... February 4, 2016 Strasbourg, France ... Inc. --> Strasbourg, France , to ... PharmaVentures is pleased to announce that it acted as ... manufacturing unit in Strasbourg, France , to ... --> --> Transgene (Euronext: TNG), a ...
(Date:2/3/2016)... 3, 2016  With the growing need for ... is underway, therapies such as monoclonal antibodies, recombinant ... host of indications are in high demand. Conventionally ... development and production of these therapeutics. However, due ... high costs, novel approaches and novel expression systems ...
(Date:2/3/2016)... ... February 03, 2016 , ... Aerocom, a world-leading supplier of ... North American healthcare market. , Aerocom Healthcare, LLC will be based in Denver, ... provide new pneumatic tube systems or expand existing systems within the U.S. and ...
Breaking Biology Technology:
(Date:1/20/2016)... MINNETONKA, Minn. , Jan. 20, 2016   ... that supports the entire spectrum of clinical research, is ... in 2015. MedNet,s significant achievements are the result of ... of) iMedNet eClinical , it,s comprehensive, ... --> --> Key MedNet growth ...
(Date:1/13/2016)... ALBANY, New York , January 13, 2016 /PRNewswire/ ... Transparency Market Research has published a new market report ... Share, Growth, Trends, and Forecast, 2015 - 2023. According to ... mn in 2014 and is anticipated to reach US$1,625.8 ... from 2015 to 2023. In terms of volume, the ...
(Date:1/8/2016)... and MANCHESTER, United Kingdom , ... a developer of innovative sensor-based diagnostic products, today announced the ... by new and existing investors.  Proceeds from the financing will ... Scanner , a hand-held device for detecting early-stage pressure ulcers. ... Ireland after receiving CE Mark approval. The ...
Breaking Biology News(10 mins):